Smartwatch-based ventilatory assessment for COPD screening: A diagnostic accuracy study
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background COPD underdiagnosis persists in China due to limited spirometry access. Smart wearables enabling cough and physiological monitoring (SpO 2 , respiratory rate) offer a scalable screening solution. Methods Participants were randomly allocated to training and validation cohorts. All underwent cough sound recordings, smartwatch monitoring (heart rate variability, respiratory rate, oxygen saturation), and pre-/post-bronchodilator spirometry. Machine learning algorithms extracted cough sound features to predict lung function (evaluated via MAE, Pearson correlation, and Bland-Altman analysis). These predictions were combined with physiological data in a multimodal COPD screening model, with diagnostic performance assessed against physician diagnosis. Results The training cohort included 178 patients (112 males) with COPD or pulmonary dysfunctions, aged 54.42 ± 14.77 years, BMI 24.81 ± 3.73 kg/m², FVC 3.64 ± 1.09 L, and FEV 1 2.42 ± 0.96 L, alongside 298 healthy volunteers (151 males) aged 35.3 ± 12.35 years, BMI 22.62 ± 3.12 kg/m², FVC 3.63 ± 0.89 L, and FEV 1 3.14 ± 0.73 L. The validation cohort comprised 47 COPD patients (35 males) aged 65.53 ± 7.62 years, BMI 25.38 ± 4.38 kg/m², FVC 3.27 ± 0.59 L, and FEV 1 1.91 ± 0.50 L, and 71 healthy controls (27 males) aged 45.51 ± 12.15 years, BMI 25.79 ± 4.00 kg/m², FVC 3.35 ± 0.80 L, and FEV 1 2.72 ± 0.67 L. Using cough sounds, the model's mean absolute error for FEV 1 /FVC, FVC%, and FEV 1 % prediction was 7.4%, 10.6%, and 17.78% ( Table 3 – 5 ), respectively, compared to spirometry. Significant correlations were found between predicted and measured FVC (r = 0.798, P < 0.001), FEV 1 (r = 0.752, P < 0.001), and FEV 1 /FVC (r = 0.784, < 0.001) ( Table 6 ). Combined with physiological parameters, our model's overall accuracy, sensitivity, and specificity for differentiating between COPD and normal controls were 87.82%, 86.96%, and 87.73% ( Table 9 ). Conclusion Our wearable-based algorithm effectively screens for ventilatory dysfunction and COPD, showing potential for large-scale population screening to reduce medical burdens. Trial Registration Chinese Clinical Trial Registry of the International Clinical Trials Registry Platform of the World Health Organization ChiCTR2100050843; Registration Date: 2021-9-4 Clinical Trial Number: ChiCTR2100050843. https://www.chictr.org.cn/showproj.html?proj=126556
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Smartwatch-based ventilatory assessment for COPD screening: A diagnostic accuracy study
- Date Crossref
- 01/05/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chinese PLA General Hospital Department of Pulmonary and Critical Care Medicine pays non établi dans la noticeÉtablissement de santé
-
Huawei Technologies (China) pays non établi dans la noticeEntreprise
-
Ltd Huawei Device Co. pays non établi dans la noticeEntreprise
-
Chinese Association of Geriatric Research pays non établi dans la noticeOrganisation à but non lucratif
Department of Pulmonary and Critical Care Medicine — Chinese PLA General Hospital, Huawei Technologies (China) et Huawei Device Co. — Ltd, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.